US20190100512A1 - Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof - Google Patents

Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof Download PDF

Info

Publication number
US20190100512A1
US20190100512A1 US15/537,331 US201515537331A US2019100512A1 US 20190100512 A1 US20190100512 A1 US 20190100512A1 US 201515537331 A US201515537331 A US 201515537331A US 2019100512 A1 US2019100512 A1 US 2019100512A1
Authority
US
United States
Prior art keywords
compound
crystalline form
formula
xrpd pattern
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/537,331
Other languages
English (en)
Inventor
Hon-Wah Man
Timothy D. Fitzpatrick
Anthony FRANK
Ying Li
Xiaoling Lu
Marie G. Beauchamps
Antonio C. Ferretti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Priority to US15/537,331 priority Critical patent/US20190100512A1/en
Assigned to CELGENE CORPORATION reassignment CELGENE CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LU, XIAOLING, LI, YING, BEAUCHAMPS, MARIE G., FERRETTI, ANTONIO C., FRANK, ANTHONY J., MAN, HON-WAH
Assigned to VENTIRX PHARMACEUTICALS, INC. reassignment VENTIRX PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FITZPATRICK, TIMOTHY D.
Assigned to CELGENE CORPORATION reassignment CELGENE CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: VENTIRX PHARMACEUTICALS, INC.
Publication of US20190100512A1 publication Critical patent/US20190100512A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
US15/537,331 2014-12-16 2015-12-15 Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof Abandoned US20190100512A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/537,331 US20190100512A1 (en) 2014-12-16 2015-12-15 Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462092764P 2014-12-16 2014-12-16
PCT/US2015/065755 WO2016100302A2 (en) 2014-12-16 2015-12-15 Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof
US15/537,331 US20190100512A1 (en) 2014-12-16 2015-12-15 Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/065755 A-371-Of-International WO2016100302A2 (en) 2014-12-16 2015-12-15 Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/570,191 Continuation US10604510B2 (en) 2014-12-16 2019-09-13 Solid forms comprising (1E, 4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[B]azepine-4-carboxami compositions thereof, and uses thereof

Publications (1)

Publication Number Publication Date
US20190100512A1 true US20190100512A1 (en) 2019-04-04

Family

ID=56127832

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/537,331 Abandoned US20190100512A1 (en) 2014-12-16 2015-12-15 Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof
US16/570,191 Expired - Fee Related US10604510B2 (en) 2014-12-16 2019-09-13 Solid forms comprising (1E, 4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[B]azepine-4-carboxami compositions thereof, and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/570,191 Expired - Fee Related US10604510B2 (en) 2014-12-16 2019-09-13 Solid forms comprising (1E, 4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[B]azepine-4-carboxami compositions thereof, and uses thereof

Country Status (12)

Country Link
US (2) US20190100512A1 (pt)
EP (1) EP3233088A4 (pt)
JP (2) JP6707088B2 (pt)
KR (1) KR20170118700A (pt)
AU (1) AU2015362720B2 (pt)
BR (1) BR112017012646A2 (pt)
CA (1) CA2970358A1 (pt)
EA (1) EA201791346A1 (pt)
IL (1) IL252744A0 (pt)
MX (1) MX2017007955A (pt)
SG (1) SG11201704791WA (pt)
WO (1) WO2016100302A2 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10604510B2 (en) 2014-12-16 2020-03-31 Celgene Corporation Solid forms comprising (1E, 4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[B]azepine-4-carboxami compositions thereof, and uses thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10239862B2 (en) 2017-03-15 2019-03-26 Silverback Therapeutics, Inc. Benzazepine compounds, conjugates, and uses thereof
CN109320456A (zh) * 2018-11-16 2019-02-12 天津商业大学 新晶型的抗肿瘤化合物及其制备方法和含其的组合物
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
AU2021300362A1 (en) 2020-07-01 2023-02-23 ARS Pharmaceuticals, Inc. Anti-ASGR1 antibody conjugates and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
CZ20022332A3 (cs) * 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
TWI404537B (zh) * 2005-08-19 2013-08-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
JP5600104B2 (ja) * 2008-08-01 2014-10-01 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッド Ｔｏｌｌ様受容体アゴニスト処方物およびその使用
ES2705101T3 (es) * 2008-11-06 2019-03-21 Ventirx Pharmaceuticals Inc Métodos de síntesis de derivados de benzazepinas
RU2587061C2 (ru) * 2010-10-01 2016-06-10 Вентиркс Фармасьютикалз, Инк. Способы лечения аллергических заболеваний
BR112017012646A2 (pt) 2014-12-16 2018-01-02 Celgene Corporation Formas sólidas compreendendo (1e, 4e)-2-amino- n,n-dipropil-8-(4-(pirrolidina-1-carbonil) fenil)-3h- benzo[b]azepina-4-carboxamida, composições das mesmas, e uso das mesmas

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10604510B2 (en) 2014-12-16 2020-03-31 Celgene Corporation Solid forms comprising (1E, 4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[B]azepine-4-carboxami compositions thereof, and uses thereof

Also Published As

Publication number Publication date
KR20170118700A (ko) 2017-10-25
IL252744A0 (en) 2017-08-31
JP6707088B2 (ja) 2020-06-10
EP3233088A4 (en) 2018-09-19
AU2015362720B2 (en) 2019-11-21
US10604510B2 (en) 2020-03-31
EP3233088A2 (en) 2017-10-25
EA201791346A1 (ru) 2018-01-31
US20200002316A1 (en) 2020-01-02
MX2017007955A (es) 2018-02-19
WO2016100302A3 (en) 2016-09-15
BR112017012646A2 (pt) 2018-01-02
CA2970358A1 (en) 2016-06-23
JP2020079261A (ja) 2020-05-28
JP2017537962A (ja) 2017-12-21
WO2016100302A2 (en) 2016-06-23
SG11201704791WA (en) 2017-07-28
AU2015362720A1 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
US10604510B2 (en) Solid forms comprising (1E, 4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[B]azepine-4-carboxami compositions thereof, and uses thereof
US9676774B2 (en) Compounds and compositions for treatment of cancer
US20090291991A1 (en) Isoindoline compounds and methods of their use
US20100129363A1 (en) Methods and compositions using pde4 inhibitors for the treatment and management of cancers
CA2545128C (en) Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
US20180000808A1 (en) Solid forms comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof
US9839632B2 (en) Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
US10159675B2 (en) Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione
US20180258064A1 (en) Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
WO2006063762A1 (en) Dipeptide nitriles
WO2024064646A1 (en) Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same

Legal Events

Date Code Title Description
AS Assignment

Owner name: CELGENE CORPORATION, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MAN, HON-WAH;FRANK, ANTHONY J.;LI, YING;AND OTHERS;SIGNING DATES FROM 20150218 TO 20180219;REEL/FRAME:045916/0096

Owner name: CELGENE CORPORATION, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VENTIRX PHARMACEUTICALS, INC.;REEL/FRAME:045916/0125

Effective date: 20170601

Owner name: VENTIRX PHARMACEUTICALS, INC., WASHINGTON

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FITZPATRICK, TIMOTHY D.;REEL/FRAME:045916/0110

Effective date: 20150223

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION